1 Min Read
* Orexigen Therapeutics announces third quarter 2017 financial results
* Q3 loss per share $1.35
* Q3 revenue $18.9 million Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.